Potent and highly selective aromatase (CYP19) inhibitor (IC50
= 15 nM) that has no discernible effect on adrenocorticoid hormone synthesis. Reduces plasma estrogen levels and exhibits antitumor activity in vivo
. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes only under agreement from AstraZeneca
The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033)-a potent, selective aromatase inhibitor.
Dukes et al.
J.Steroid Biochem.Mol.Biol., 1996;58:439
Anastrozole: a new selective nonsteroidal aromatase inhibitor.
Goss and Tye
Anastrozole (ArimidexTM) - an aromatase inhibitor for the adjuvant setting?